CERADON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CERADON (CERADON).
Unknown; possibly enhances cognitive function by modulating cholinergic and dopaminergic pathways.
| Metabolism | Hepatic, primarily via CYP3A4 and CYP2D6. |
| Excretion | Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total: >90% eliminated within 48 hours. |
| Half-life | 3-5 hours in healthy adults; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20 hours in severe impairment (CrCl <30 mL/min). |
| Protein binding | 85-92% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive distribution into total body water and tissues. |
| Bioavailability | Oral: 75-85% (first-pass metabolism ~15-25%); intramuscular: 90-95%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 2-5 minutes; intramuscular: 15-30 minutes. |
| Duration of Action | Oral: 4-6 hours; intravenous: 2-4 hours; clinical effect correlates with plasma concentration above 2 mcg/mL. |
| Molecular Weight | 427.5 |
500 mg orally every 8 hours; for severe infections, 750 mg every 12 hours or 1 g every 8 hours.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl >50 mL/min: no adjustment. CrCl 30-50 mL/min: 500 mg every 12 hours. CrCl 10-29 mL/min: 500 mg every 24 hours. Hemodialysis: 500 mg after each dialysis session. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: not recommended. |
| Pediatric use | For children >1 month: 30 mg/kg/day divided every 8 hours, max 1 g/day. For severe infections: 40 mg/kg/day divided every 8 hours, max 1.5 g/day. Administer orally. |
| Geriatric use | Start at low end of dosing range (e.g., 250 mg every 12 hours) due to age-related renal decline. Adjust based on renal function; monitor for increased risk of arrhythmias and CNS effects. |
| 1st trimester | Avoid. Teratogenic in animal studies; human data insufficient. |
| 2nd trimester | Avoid. Due to potential fetal toxicity. |
| 3rd trimester | Avoid. Risk of neonatal toxicity and adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for CERADON (CERADON).
| Placental transfer | Yes, extensive placental transfer documented in animal and human studies. |
| Breastfeeding | Excreted in breast milk; may cause adverse effects in nursing infants. Use is contraindicated during breastfeeding. |
| Lactation Rating | L5 (Contraindicated) |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to CERADONSevere hepatic impairmentBreastfeeding
| Precautions | May cause extrapyramidal symptoms; use with caution in patients with hepatic impairment; monitor for neuropsychiatric adverse events. |
| Food/Dietary | Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition increasing CERADON levels. Avoid high-fat meals as they may impair absorption. Limit alcohol intake as it can exacerbate CNS depression and hypotension. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk | Pregnancy Category D: Positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or human studies, but potential benefits may warrant use in pregnant women despite potential risks. First trimester: Risk of congenital malformations including cardiovascular and neural tube defects. Second trimester: Risk of intrauterine growth restriction and oligohydramnios. Third trimester: Risk of preterm labor and fetal distress. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and liver enzymes every 2 weeks. Assess fetal growth by ultrasound every 4 weeks. Perform non-stress test and biophysical profile weekly after 32 weeks gestation. Monitor amniotic fluid index for oligohydramnios. |
| Fertility Effects | CERADON may cause reversible infertility in females by disrupting ovarian cycle and reducing ovarian reserve. In males, it may reduce sperm count and motility. Contraception should be used during treatment and for 3 months after discontinuation. |
| CERADON is a serotonin-dopamine activity modulator. Titrate slowly to minimize orthostatic hypotension, especially in elderly. Monitor QTc interval at baseline and after dose increases due to risk of QTc prolongation. May cause extrapyramidal symptoms; use extrapyramidal symptom rating scales. Avoid abrupt discontinuation to prevent withdrawal dyskinesia. Has clinically significant CYP2D6 inhibition; adjust doses of concomitant CYP2D6 substrates. |
| Patient Advice | Take exactly as prescribed; do not change dose without consulting your doctor. · Avoid driving or operating heavy machinery until you know how this medication affects you, as it may cause dizziness or drowsiness. · Rise slowly from sitting or lying positions to prevent falls due to blood pressure drop. · Report any fast, pounding heartbeats, fainting, or muscle stiffness, as these may be signs of serious side effects. · Avoid alcohol and grapefruit juice while taking CERADON. · Do not stop taking abruptly; your doctor will advise a gradual taper to prevent withdrawal symptoms. |